FDA free to pursue semaglutide compounders after latest court ruling
Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final resolution.

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final resolution.
AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal
3 reasons why biotechs preparing for launch need a compliant content foundation
Google-backed Isomorphic Labs raises $600m to advance AI drug discovery
EU Health Data Space strikes a chord in EU harmonisation plans